Adamas Pharma (ADMS) Offers Additional Data from ADS-5102 Phase 3 in LID; Improvement in All Subgroups Noted
Tweet Send to a Friend
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release capsules ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
